The invention provides a kit for detecting lymphoid 
blood cancers such as T / B 
leukemia, 
lymphoma and myeloma minimal residual diseases based on research and development of high-
throughput sequencing.The kit comprises 
multiplex-PCR primer sets for detecting IGH(VDJ), IGH(DJ), IGK, IGL, TCRbeta, TCRgamma, TCRdelta, BCL1 / IGH and BCL2 / IGH and with UMB (Unique Molecular 
Barcode, single-molecular labels), House Keeping 
gene PCR primer pairs, 
Multiplex PCR Mix(2X), internal reference 
DNA, 
Nuclease-
Free Water, 
Elution Buffer, and primers and 
label sequences required for high-
throughput sequencing. Bythe adoption of the kit, newly-
mutant cancer cells can be found while the 
cancer cells are detected, the high-
throughput sequencing technology is applied and combined with bioinformatic analysis, forthe detection sensitivity of MRD, one 
cancer cell can be at least detected in 1 
million cells, that is to say, the probability is 10<-6>(0.0001%), the purpose of detecting the minimal residual diseases through quantitative analysis of the number of the cancer cells can be achieved, and sequence reading errors generated in the sequence 
mutation and 
library sequencing process due to base group mismatch during PCR amplification can be corrected.